

Characterization of antiseizure medications effects on the EEG neurodynamic by fractal dimension

Porcaro, Camillo; Seppi, Dario; Pellegrino, Giovanni; Dainese, Filippo; Kassabian, Benedetta; Pellegrino, Luciano; De Nardi, Gianluigi; Grego, Alberto; Corbetta, Maurizio; Ferreri, Florinda

DOI:

[10.3389/fnins.2024.1401068](https://doi.org/10.3389/fnins.2024.1401068)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Porcaro, C, Seppi, D, Pellegrino, G, Dainese, F, Kassabian, B, Pellegrino, L, De Nardi, G, Grego, A, Corbetta, M & Ferreri, F 2024, 'Characterization of antiseizure medications effects on the EEG neurodynamic by fractal dimension', *Frontiers in Neuroscience*, vol. 18, 1401068. <https://doi.org/10.3389/fnins.2024.1401068>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



OPEN ACCESS

EDITED BY

Adeel Razi,
Monash University, Australia

REVIEWED BY

Wenhai Zhang,
Hengyang Normal University, China
Zongyue Cheng,
Purdue University, United States
Stefania Coelli,
Polytechnic University of Milan, Italy

*CORRESPONDENCE

Camillo Porcaro
✉ camillo.porcaro@unipd.it

†These authors have contributed equally to
this work

RECEIVED 14 March 2024

ACCEPTED 20 May 2024

PUBLISHED 07 June 2024

CITATION

Porcaro C, Seppi D, Pellegrino G, Dainese F,
Kassabian B, Pellegrino L, De Nardi G,
Grego A, Corbetta M and Ferreri F (2024)
Characterization of antiseizure medications
effects on the EEG neurodynamic by fractal
dimension.
Front. Neurosci. 18:1401068.
doi: 10.3389/fnins.2024.1401068

COPYRIGHT

© 2024 Porcaro, Seppi, Pellegrino, Dainese,
Kassabian, Pellegrino, De Nardi, Grego,
Corbetta and Ferreri. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Characterization of antiseizure medications effects on the EEG neurodynamic by fractal dimension

Camillo Porcaro^{1,2,3*}, Dario Seppi^{4,5}, Giovanni Pellegrino⁶,
Filippo Dainese^{4,5}, Benedetta Kassabian^{4,5}, Luciano Pellegrino^{4,5},
Gianluigi De Nardi^{4,5}, Alberto Grego^{4,5}, Maurizio Corbetta^{1,4,7†}
and Florinda Ferreri^{1,4,5†}

¹Department of Neuroscience and Padova Neuroscience Center (PNC), University of Padova, Padova, Italy, ²Institute of Cognitive Sciences and Technologies (ISTC) – National Research Council (CNR), Rome, Italy, ³Centre for Human Brain Health, School of Psychology, University of Birmingham, Birmingham, United Kingdom, ⁴Neurology Clinics, Azienda Ospedale Università, Padua, Italy, ⁵Unit of Clinical Neurophysiology, Azienda Ospedale Università, Padua, Italy, ⁶Epilepsy Program, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁷Veneto Institute of Molecular Medicine (VIMM), Fondazione Biomedica, Padua, Italy

Objectives: An important challenge in epilepsy is to define biomarkers of response to treatment. Many electroencephalography (EEG) methods and indices have been developed mainly using linear methods, e.g., spectral power and individual alpha frequency peak (IAF). However, brain activity is complex and non-linear, hence there is a need to explore EEG neurodynamics using nonlinear approaches. Here, we use the Fractal Dimension (FD), a measure of whole brain signal complexity, to measure the response to anti-seizure therapy in patients with Focal Epilepsy (FE) and compare it with linear methods.

Materials: Twenty-five drug-responder (DR) patients with focal epilepsy were studied before (t1, named DR-t1) and after (t2, named DR-t2) the introduction of the anti-seizure medications (ASMs). DR-t1 and DR-t2 EEG results were compared against 40 age-matched healthy controls (HC).

Methods: EEG data were investigated from two different angles: frequency domain—spectral properties in δ , θ , α , β , and γ bands and the IAF peak, and time-domain—FD as a signature of the nonlinear complexity of the EEG signals. Those features were compared among the three groups.

Results: The δ power differed between DR patients pre and post-ASM and HC (DR-t1 vs. HC, $p < 0.01$ and DR-t2 vs. HC, $p < 0.01$). The θ power differed between DR-t1 and DR-t2 ($p = 0.015$) and between DR-t1 and HC ($p = 0.01$). The α power, similar to the δ , differed between DR patients pre and post-ASM and HC (DR-t1 vs. HC, $p < 0.01$ and DR-t2 vs. HC, $p < 0.01$). The IAF value was lower for DR-t1 than DR-t2 ($p = 0.048$) and HC ($p = 0.042$). The FD value was lower in DR-t1 than in DR-t2 ($p = 0.015$) and HC ($p = 0.011$). Finally, Bayes Factor analysis showed that FD was 195 times more likely to separate DR-t1 from DR-t2 than IAF and 231 times than θ .

Discussion: FD measured in baseline EEG signals is a non-linear brain measure of complexity more sensitive than EEG power or IAF in detecting a response to ASMs. This likely reflects the non-oscillatory nature of neural activity, which FD better describes.

Conclusion: Our work suggests that FD is a promising measure to monitor the response to ASMs in FE.

KEYWORDS

quantitative-EEG, focal epilepsy, antiseizure medications, biomarkers, fractal dimension

1 Introduction

Epilepsy represents one of the most common neurological conditions, affecting up to 1% of the world population. The clinical management of epilepsy patients is largely based on clinical judgment and is essentially qualitative. For instance, the choice of the first medication—after a diagnosis of epilepsy is made—is based on the clinical features of the seizures and the potential side effect profile of the medication. Similarly, the efficacy of response is established based on the reduction of the number of seizures or the qualitative improvement of inter-ictal EEG signals. Currently, there are no quantitative biomarkers for the prediction of pharmacological efficacy at the population or individual patient level.

The objective of this study is to quantitatively assess the effects of ASMs on brain signals to predict the likelihood of response through an automated algorithm leveraging quantitative analysis of clinical EEGs (qEEG) (Park et al., 2020). Quantitative EEG is a promising branch of clinical neurophysiology that explores local and global brain dynamics. When coupled with drugs (Jobert et al., 2012) qEEG is a promising tool to study the response to new drugs and has become an established technique for their classification (Galderisi et al., 1994; Mucci et al., 2006; Fink, 2010; Iosifescu, 2011).

So far, the two most reliable EEG biomarkers of ASM response are the interictal epileptiform discharges and the power spectral analysis, while the use of the Individual Alpha Frequency (IAF) peak is still debated but may represent a promising biomarker (Reynolds et al., 2023). However, these linear methods mainly capture the oscillatory component of the EEG signal and do not consider non-stationarities and non-linearities present in EEG signals (Stam, 2005; Klonowski, 2009). As stated by Cole and Voytek and by Jones and colleagues (Jones, 2016; Cole and Voytek, 2017), brain signals do not simply represent a sustained oscillation at a particular frequency but rather brief bouts of activity that repeat intermittently (Feingold et al., 2015; Lundqvist et al., 2016). Neuromodulation studies demonstrate that the application of complex and non-sinusoidal waveforms is more effective than sinusoidal oscillators in modulating brain (Somers and Kopell, 1993; Fröhlich and McCormick, 2010; Fröhlich, 2015; Dowsett and Herrmann, 2016; Cottone et al., 2018; Porcaro et al., 2019) and entraining brain rhythms (Somers and Kopell, 1993; Dowsett and Herrmann, 2016). This “hidden information” captured by non-linear methods such as fractal dimension analysis may be additional and complementary to linear methods and could shed light on the physiological neural communication, computation, and cognition in healthy as well as patients with neuropathological conditions (Goldberger, 2001; Goldberger et al., 2002; Zhang and Raichle, 2010; Rodríguez-Bermúdez and García-Laencina, 2015; Porcaro et al., 2017, 2019, 2020a,b, 2022). This is the reason why time-series fractal analysis is more and more used in different research fields ranging from basic

neuroscience (Di Ieva et al., 2014, 2015; Moaveninejad et al., 2024), neurophysiology (Adeli et al., 2008; Ahmadlou and Adeli, 2012; Ahmadlou et al., 2012a,b), translational neuroscience (Smits et al., 2016; Porcaro et al., 2020b, 2021, 2022; Fiorenzato et al., 2024; Olejarczyk et al., 2024) to genetic variability in human phenotypes (Cattani and Pierro, 2013; Lee, 2020; Borri et al., 2022).

The purpose of our study is, therefore, to compare EEG signals in newly diagnosed patients with focal epilepsy patients before and after the initiation of therapy and examine their normalization using both linear (power spectra and IAF) and non-linear methods (FD). Specifically, we are interested in evaluating which method is more sensitive in detecting differences pre- and post-therapy with ASMs.

2 Materials and methods

2.1 Patients and data collection

We retrospectively reviewed the data of 25 newly diagnosed focal epilepsy patients and a control group of 40 healthy subjects enrolled at the epilepsy clinic of the Neurophysiological Unit of the Padua University Hospital (see Table 1). Epilepsy patients fulfilling the following inclusion criteria were included: (i) focal epilepsy according to the International League Against Epilepsy diagnostic recommendations (Scheffer et al., 2017); (ii) >16 years old; (iii) no previous ASMs therapy (drug-naïve patients); (iv) at least two routine EEGs performed before (i.e., <30 days – DR-t1) and 6–12 months after (DR-t2) the beginning of treatment; (v) EEGs included 5+ min of artifact free wakefulness; (vi) clinical follow-up at two-years. The exclusion criteria were: (i) other drugs acting on the CNS; (ii) medication change between EEG recordings. All patients underwent neurophysiological assessment, EEG, and brain MRI, as per standard of care (Koutroumanidis et al., 2017a,b; Scheffer et al., 2017).

Healthy subjects were volunteers. They were interviewed by a neurologist to rule out medical conditions potentially biasing the study. Healthy subjects met the following inclusion criteria: (i) age >16 years; (ii) no medical or psychiatric conditions; (iii) no neuroactive drugs.

The study protocol was approved by Padua University Hospital's ethics committee for a retrospective study.

2.2 EEG recording

Nineteen channel EEG was acquired with a EB-Neuro Galileo (Mizar 40) recorder. The electrodes were placed according to the international 10–20 system (Fp1, Fp2, F3, F4, C3, C4, P3, P4, F7, F8, T3, T4, T5, T6, O1, O2, Fz, Cz, Pz). The reference was placed on FPz

TABLE 1 Demographic characteristics of the sample by group.

Group	N.	Age (years)		Gender		Etiology		Drug		
		Mean	SD	F	M	U	S	LEV	LTG	LCM
EPI	25	39.8	17.0	18	7	18	7	15	5	5
HC	40	38.9	16.0	23	17					

EPI, focal epilepsy patients; HC, healthy controls; N, number of individuals; SD, standard deviation; U, Unknown origin; S, Structural origin; LEV, Levetiracetam; LTG, Lamotrigine; LCM, Lacosamide.

and the ground on FCz. Impedance was kept below 10 kOhm for all electrodes. The sampling rate was set to 256 Hz. EEG recordings for patients lasted at least 20 min as per standard of care. This included 5 min of EEG eyes closed, which was selected for the purpose of this study. The remaining 15 min included eyes open recording, reactivity to eye closure and opening, intermittent photic stimulation, and hyperventilation, as per common clinical practice. The healthy control group performed 5 min of EEG recordings with open eyes and 5 min of EEG recordings with closed eyes.

2.3 EEG pre-processing

Quantitative EEG analysis was performed using the EEGLab Toolbox for Matlab¹ and in-home Matlab code. Offline data pre-processing included: (i) visual inspection for rejection of possible interictal and ictal epileptiform activity; (ii) DC removal; (iii) bandpass filter between 1 and 48 Hz (linear phase finite impulse response filter); (iv) EEG re-reference to average; (v) correction for pulse and eye blink artifacts using Independent Component Analysis (ICA) (Barbati et al., 2004; Porcaro et al., 2015). Visual identification of interictal and ictal abnormalities was performed by experienced neurophysiologists blind to the clinical data as well as 5 min of EEG eyes closed (FE, CL, FD).

2.4 Characterization of electrophysiological neural activity at rest

We considered signal properties in the frequency domain (PSD) and time domain. The PSD is the squared modulus of the continuous Fourier transform. It is particularly useful for studying brain oscillations on a time scale of minutes, typical of an individual's "stable state" (Schomer and Lopes Da Silva, 2012). As for the time domain, the signal power of neuronal assemblies, as a function of frequency, displays a "power law" function (Ramon and Holmes, 2015), and the exponent of this function corresponds to its fractality. Thus, we used temporal Higuchi's fractal dimension (FD) (Higuchi, 1988) as a signature of neural dynamics underlying brain functions.

2.5 EEG power spectrum

We calculated the PSD using the Welch procedure (256 time points duration, Hanning window, and 60% overlap). We then investigated

the spectral properties of the EEG total power in the classical frequency bands, such as δ (1–3 Hz), θ (4–7 Hz), α (8–13 Hz), β (14–30 Hz), and γ (31–48 Hz) bands (Chatrian et al., 1974). In addition, IAF was defined as the exact frequency in the α range containing the maximum power. It was calculated using an automated peak-detection algorithm (function RestingIAF on EEGLab) (Corcoran et al., 2018).

2.6 Higuchi's fractal dimension

FD (Higuchi, 1988) is a non-linear measure of waveform complexity applied in the time domain. Discretised functions or signals can be analyzed as a segment of data $X(1), X(2), \dots, X(N)$, where N is the total number of samples. From the starting time sequence, a new self-similar time series X_m^k can be calculated as Eq. 1:

$$X_m^k : x(m), x(m+k), x(m+2k), \dots, x\left(m + \text{int}\left(\frac{N-m}{k}\right)k\right) \quad (1)$$

for $m = 1, 2, \dots, k$ where m is the initial time; k is the time interval, $k = 1, 2, \dots, k_{max}$; k_{max} is a free parameter, and $\text{int}()$ represent the integer operator.

The length, $L_m(k)$, of each curve X_m^k is calculated as Eq. 2:

$$L_m(k) = \frac{1}{k} \left[\sum_{i=1, \text{int}\left(\frac{N-m}{k}\right)}^{N-1} |X(m+ik) - X(m+(i-1)k)| \frac{N-1}{\text{int}\left(\frac{N-m}{k}\right)k} \right] \quad (2)$$

where N is the length of the original time series X and $\left[\frac{N-1}{\text{int}\left(\frac{N-m}{k}\right)k} \right]$ is a normalization factor.

$L_m(k)$ was averaged across all m forming the mean value of the curve length $L(k)$ for each $k = 1, \dots, k_{max}$ as Eq. 3:

$$L(k) = \frac{\sum_{m=1}^k L_m(k)}{k} \quad (3)$$

An array of mean values $L(k)$ was obtained and the FD was estimated as Eq. 4:

$$FD = \log(L(k)) / \log(1/k) \quad \text{for } k = 1, 2, \dots, k_{max} \quad (4)$$

¹ <https://sccn.ucsd.edu/eeglab/index.php>

In practice, the original curve or signal can be divided into smaller parts with or without overlap, called “windows.” Then, the method for computing the FD should be applied to each window where N should be seen as the length of the window. Individual FD values can be averaged across all windows for the entire curve (or data time-series), and the mean FD value can be used as a measure of curve complexity. Additional analysis demonstrated that FD measurements were not dependent on the choice of window length and overlapping windows see [Smits et al. \(2016\)](#), [Marino et al. \(2019\)](#), and [Porcaro et al. \(2020a\)](#) for details. Here, for each EEG channel, we calculated FD in non-overlapping time windows of 1 s (corresponding to 256-time points since our sample frequency rate was 256 Hz) as a good compromise between the window length of the data and computational time. The choice of the free parameter k has a crucial role in FD estimation; for this reason, for each window, we estimated 127 values of FD for all the possible k values (i.e., $k = 2, \dots, 128$).

The value 128 was equal to half of the samples within our 1 s window (i.e., 128-time points are the maximum that can be chosen since the maximum k value is equal to half of the window length). For the subsequent FD analysis, we set $k = 25$ ([Smits et al., 2016](#); [Marino et al., 2019](#); [Porcaro et al., 2020a, 2022](#)).

2.7 Statistical analysis

Shapiro–Wilk test for normality revealed that PSD, IAF, and FD values did not differ from a Gaussian distribution ($p > 0.200$). Repeated-measures analysis of variance (rm-ANOVA) was performed on PSD values to investigate the interaction effect GROUPS \times BANDS (the three GROUPS as a between-subject factor: DR-t1, DR-t2, and HC); the five BANDS as a within-subjects factor ($\delta, \theta, \alpha, \beta, \gamma$). The sphericity of the covariance matrix was verified with the Mauchly sphericity test. In the case of violation of the sphericity assumption, the Greenhouse–Geisser epsilon adjustment was used. One-way ANOVA was also applied to investigate the GROUPS effect (between-subject factor: DR-t1, DR-t2, and HC) on FD and IAF. The results were analyzed only for all ANOVA models if the Wilks’ Lambda multivariate significance criterion was achieved. In the case of violation of the sphericity assumption, the Greenhouse–Geisser epsilon adjustment was used. *Post-hoc* analysis was performed using the Bonferroni correction method for multiple comparisons. Finally, the three measures (PSD, IAF, and FD) were analyzed using a Bayesian approach to test which of the three methods was better able to discriminate between DR-t1 and DR-t2 conditions. We have performed the same ANOVA test as above on a single drug to test for any drug specificity. The drug chosen was LEV since it has higher numerosity, with the number of subjects being 15. All the analyses described above were conducted in JASP software (v0.17.2-1—jasp-stats.org/).

3 Results

3.1 Demographic results

A one-way ANOVA model found no significant age difference among groups [$F(2, 89) = 2.24, p = 0.129$].

3.2 EEG power spectrum and IAF

3.2.1 All drugs (LEV, LTG, LCM)

A repeated measure ANOVA (rm-ANOVA) for the PSD with a Greenhouse–Geisser correction (Mauchly’s $W = 0.005, p < 0.001, \epsilon = 0.369$) revealed a significant GROUP \times BAND interaction [$F(8, 356) = 16.4, p < 0.001$]. The between-subjects factor GROUP also showed a difference [$F(2, 89) = 26.1, p < 0.001$]. *Post-hoc* tests using the Bonferroni correction revealed that the δ band was different between DR-t1 and HC ($p < 0.001$) and between DR-t2 and HC ($p < 0.001$). There was no significant difference between DR-t1 and DR-t2. The θ band differed between DR-t1 and DR-t2 ($p = 0.015$) and DR-t1 and HC ($p = 0.01$), but not between DR-t2 and HC. Finally, the α band significantly differed between DR-t1 and HC and between DR-t2 and HC ($p = 0.002$ for both), but there was no difference between DR-t1 and DR-t2. No significant differences were found for other frequency bands ([Figure 1A](#)). The IAF ANOVA model revealed a statistically significant difference between GROUPS [$F(2, 89) = 3.29, p = 0.042$]. Bonferroni corrected *post-hoc* tests revealed that the IAF value was lower for the DR-t1 as compared to the DR-t2 ($p < 0.048$) and the HC group ($p = 0.042$). No difference was observed for the DR-t2 vs. HC ([Figure 2A, Up](#)).

3.2.2 Only LEV

rm-ANOVA for the PSD with a Greenhouse–Geisser correction (Mauchly’s $W = 0.0113, p < 0.001, \epsilon = 0.410$) revealed a significant GROUP \times BAND interaction [$F(8, 268) = 14.2, p < 0.001$]. The between-subjects factor GROUP also showed a difference [$F(2, 67) = 18.9, p < 0.001$]. *Post-hoc* tests using the Bonferroni correction revealed that the δ band was different between DR-t1 and HC ($p < 0.001$) and between DR-t2 and HC ($p < 0.001$). There was no significant difference between DR-t1 and DR-t2. The θ band differed between DR-t1 and DR-t2 ($p = 0.008$) and DR-t1 and HC ($p = 0.001$), but not between DR-t2 and HC. Finally, the α band significantly differed between DR-t1 and HC ($p = 0.015$) and between DR-t2 and HC ($p = 0.006$), but there was no difference between DR-t1 and DR-t2. No significant differences were found for other frequency bands ([Figure 1B](#)). The IAF ANOVA model only showed a tendency to significantly differ between GROUPS [$F(2, 67) = 2.455, p = 0.09$; [Figure 2B, Up](#)].

3.3 Higuchi’s fractal dimension

3.3.1 All drugs (LEV, LTG, LCM)

The ANOVA model for the FD feature also revealed a significant GROUP effect for FD [$F(2, 89) = 5.537, p = 0.005$]. Bonferroni corrected *post-hoc* tests revealed that FD was lower for DR-t1 compared to DR-t2 ($p = 0.015$) and the HC group ($p = 0.011$). No significant difference was found for DR-t2 vs. HC ([Figure 2A, Bottom](#)).

3.3.2 Only LEV

The ANOVA model for the FD estimated only on the LEV drug revealed a significant GROUP effect for FD [$F(2, 67) = 5.903, p = 0.004$]. Bonferroni corrected *post-hoc* tests revealed that FD was lower for DR-t1 compared to DR-t2 ($p = 0.024$) and the HC group ($p = 0.004$). No significant difference was found for DR-t2 vs. HC ([Figure 2B, Bottom](#)).




FIGURE 1

Panel (A) all drugs, Delta (Upper panel), Theta (Middle panel), and Alpha (Bottom panel) values among groups [healthy controls (HC), patients before pharmacological intervention (DR-t1), and patients after pharmacological intervention (DR-t2)]. The horizontal bar indicates which contrast reached the significant level at $p < 0.01$ (**) and $p < 0.05$ (*). Black points and error lines represent the mean and the standard error. Panel (B), as panel (A), but for only LEV drug.




FIGURE 2 Panel (A) all drugs, IAF (Upper panel) and FD (Bottom panel) values among groups [healthy controls (HC), patients before pharmacological intervention (DR-t1), and patients after pharmacological intervention (DR-t2)]. The horizontal bar indicates which contrast reached the significant level at $p < 0.01$ (**), $p < 0.05$ (*) and (+) $p = 0.09$. Black points and error lines represent the mean and the standard error. Panel (B), as panel (A), but for only LEV drug.

3.4 Is FD more sensitive than PSD or IAF in detecting drug response effects?

We used Bayesian Paired samples *t*-tests to compare the relative sensitivity of FD vs. PSD in discriminating DR-t1 vs. DR-t2 patients. There are several advantages to using Bayesian methods. First, Bayesian methods allow inferences about both the null and alternative hypotheses. Second, it is possible to compare Bayes Factors (BF) across analyses and, based on the magnitude of the BF, derive whether one result is more robust than another.

We found a significant difference between DR-t1 and DR-t2 for FD [Student's $t(25) = -5.172, p < 0.001, BF_{10} = 973.069$], θ band power [Student's $t(25) = 2.730, p = 0.011, BF_{10} = 4.220$], and IAF [Student's $t(25) = -2.816, p = 0.009, BF_{10} = 4.994$]. However, the magnitude of BF was higher for FD than θ band or IAF (BF FD = 973.069; BF θ band = 4.994; BF IAF = 4.220). Accordingly, FD was 195 times more likely than IAF, and 231 times more likely than θ band to distinguish DR-t1 from DR-t2. Figures 3, 4 show the descriptive statistics. In particular, Figure 3 shows the value for the θ band, IAF, and FD and each patient before and after the pharmacological intervention; the gray line that conjuncts the green circle with the orange circle

emphasizes the trend obtained for each patient. The more the trend follows the same direction (i.e., from higher to lower θ), the higher will be the statistical effects. Figure 4 displays the individual cases (green dots), box plots, and density for the difference between the measures. In our case, FD (Figure 4, Bottom panel) clearly shows that the pharmacological intervention decreases the brain complexity estimated by Higuchi's FD in all patients.

4 Discussion

The issue of assessing the response of ASMs in newly diagnosed epilepsy patients is an important clinical problem with important implications for health national systems. Research in the last 40 years has been devoted to developing EEG biomarkers as reliable indices of favorable response (Porcaro et al., 2019, 2020a, 2022; Comanducci et al., 2020). Compared to MRI and PET scans, EEG has many advantages, including low costs, widespread availability in economically less developed countries, non-invasiveness, and portability. However, EEG biomarkers are not routinely used in clinical practice to assess response. Patients are still evaluated based




FIGURE 3 Single subject representation for theta value [upper panel—before (DR-t1) and after (DR-t2) pharmacological intervention], IAF value [middle panel—before (DR-t1) and after (DR-t2) pharmacological intervention] and FD value [bottom panel—before (DR-t1) and after (DR-t2) pharmacological intervention]. Each circle represents a subject, and the gray line connects the same subject before (green circle) and after (orange circle) pharmacological intervention.

on clinical response and a qualitative evaluation of EEG recordings and interictal abnormalities.

The research area exploring the relationship between fractal dimension and epilepsy is a novel and promising field, delving into the dynamics of brain activity. The Fractal dimension is a measure of the




FIGURE 4 Single subject difference distribution density for theta value [Upper panel—before (DR-t1) and after (DR-t2) pharmacological intervention], IAF value [middle panel—before (DR-t1) and after (DR-t2) pharmacological intervention] and FD value [bottom panel—before (DR-t1) and after (DR-t2) pharmacological intervention]. Each green circle represents the subject difference for each feature under investigation (Theta Band, IAF, and FD) before and after pharmacological intervention. The green area under the curve represents its density distribution. In the box plot, the bold black line shows the sample median. The hinges indicate the 25th and 75th quantiles and the whiskers point to 1.5 interquartile ranges beyond the hinges.

irregularity or complexity of a geometric structure, such as the spatiotemporal dynamics of brain (Porcaro et al., 2024). In epilepsy, the pathological mechanism involves abnormal synchronization of neuronal activity, leading to seizures. Fractal EEG signal analysis might be a new tool to investigate this abnormal complexity of brain activity in epileptic patients (Jouny and Bergey, 2012; Khoa et al., 2012).

In healthy individuals, EEG signals exhibit a certain level of complexity, characterized by a fractal dimension within a specific range (Cottone et al., 2017; Marino et al., 2019). However, in epileptic patients, this complexity may be altered due to disruptions in the normal functioning of neural networks (Jouny and Bergey, 2012; Khoa

et al., 2012). Several studies have found differences in fractal dimension measures between healthy individuals and epileptic patients, as well as between different types of epilepsy. For example, some research suggests that the fractal dimension of EEG signals may decrease during epileptic seizures, indicating a loss of complexity in brain activity (Olejarczyk, 2003; Jouny and Bergey, 2012; Khoa et al., 2012). On this basis, fractal analysis has an enormous potential for understanding epilepsy, with implications for both diagnosis and treatment. By providing insights into the underlying mechanisms of epilepsy, this analysis could pave the way for developing more effective diagnostic tools and therapies, making it a crucial area of study.

Overall, while the exact connection between the fractal dimension and the pathological mechanism of epilepsy is still being explored, research in this area holds promise for advancing our understanding of this complex neurological disorder.

With this aim, here we used Higuchi's Fractal Dimension (FD) to investigate newly diagnosed patients with focal epilepsy from healthy controls and their response to ASMs. As a benchmark, we compared the FD to linear neurophysiological markers like the band-limited power and the IAF that have been evaluated in previous studies of response to ASMs (Clemens et al., 2007; Cho et al., 2012; Guo et al., 2014).

We found that ASMs treatment reduced θ power near normal levels, while α and δ power bands did not change pre- and post-treatment (Figure 1). ASMs also normalized the IAF and FD near the level of HC subjects (Figure 2).

Our reduction of θ band power after treatment with ASMs is generally consistent with several previous studies, and it does not appear to be drug-dependent. Patients treated with Levetiracetam showed an increase in α β power and a decrease in δ and θ power bands (Cho et al., 2012). Patients treated with Perampanel showed an increase in α power in drug responder patients (Lanzone et al., 2021). In TLE patients, Levetiracetam induced an increase in α power and a decrease in θ band power (Ricci et al., 2021). In another study, patients treated with LTG or VPA as first line therapy showed reduced θ and γ power (Clemens et al., 2007; Clemens, 2008; Guo et al., 2014). However, other studies have shown spontaneous longitudinal fluctuations in power which may confound some of the drug response effect (Viana et al., 2021).

While in our study the α power did not significantly change pre-post-treatment, the θ power normalized consistently with previous studies. In addition, we showed an increase in IAF that normalized post-therapy. The IAF is a stable index of oscillatory activity in the occipital lobe that grows in the course of development, and it is decreased in some pathological conditions (e.g., schizophrenia, Ramsay et al., 2021). A within-subject study showed that IAF was significantly higher during a demanding working memory task than during rest or passive visual stimulation (Haegens et al., 2014). Our interpretation is that the increase in IAF reflects an improvement toward normalization of cognitive processing in our patients after starting ASMs.

Overall, our results are consistent with those of other studies that have used classical FFT-based linear methods to distinguish between healthy subjects and epileptic patients and between pre- and post-ASMs (Clemens et al., 2014; Pellegrino et al., 2018; Lanzone et al., 2021).

The most novel aspect of our results is that the FD increased normalizing after ASMs. Moreover, the FD was more sensitive than θ

power and IAF in separating epileptic patients before and after treatment. The Fractal Dimension has been introduced as a marker in both healthy (Cottone et al., 2017; Marino et al., 2019; Porcaro et al., 2020a) and pathological conditions (Smits et al., 2016; Porcaro et al., 2019, 2020b, 2021, 2022). In the case of EEG, FD is a non-linear measure of signal complexity. Increased EEG synchrony results in its reduction while EEG desynchronization leads to FD increases. FD increases with task complexity (Cottone et al., 2018), and it is reduced after brain stroke (Zappasodi et al., 2014). The sensitivity of FD comes from its ability to estimate both oscillatory and non-oscillatory components of the EEG signal capturing patterns of activity that are not consistent over time. These non-rhythmic patterns have been clearly demonstrated in the human motor cortex (Feingold et al., 2015; Lundqvist et al., 2016; Cole et al., 2017; Cole and Voytek, 2017). The non-rhythmic nature of brain activity has been further supported by neuromodulation studies in which non-sinusoidal patterns were more effective in entraining brain rhythms (Somers and Kopell, 1993; Fröhlich and McCormick, 2010; Dowsett and Herrmann, 2016; Cottone et al., 2018).

Our results suggest that ASMs normalized brain activity in our focal epilepsy patients specifically by increasing signal complexity as indexed by FD. The corollary increase in IAF that has been associated with higher cognitive processing is also another neurophysiological indicator of brain activity normalization. It would have been important to show an improvement in neuropsychological scores post-therapy. It is remarkable that these changes occurred in the absence of apparent seizure activity. The large superiority of FD over oscillatory biomarkers (195 times more likely than IAF; 231 times higher than θ band) in picking up patients post-therapy is an indication that under physiological conditions brain activity is not oscillatory. To our knowledge, this is the first report to show a decrease of brain signal complexity in newly diagnosed epileptic subjects, which normalized after therapy.

5 Limitations and conclusions

The study suffers from several limitations. The sample is small, retrospective, and heterogeneous in terms of number of etiologies and drugs employed. In this respect, we have performed the ANOVA on a more heterogeneous subgroup concerning the drug (in particular, we selected the 15 subjects treated with the LEV). The ANOVA showed comparable results with respect to the results obtained with the entire group treated with different drugs (i.e., 15 LEV, 5 LTG, and 5 LCM). The robustness of our findings despite these limits may suggest that the effect is robust and even stronger in a more homogenous sample. Another limitation is that we cannot exclude that these effects underlie the normal longitudinal recovery of signal complexity after the occurrence of novel seizure activity. To rule out this possibility, it would be important to have a group of non-responders and follow them longitudinally. However, non-responders are only about 30% of all epileptic patients, and a comparison across groups would be less sensitive than a within-subject comparison as in our study. The mean change in IAF pre- post-therapy was, on average ~ 0.5 Hz which is on par with within-subject IAF variability (~ 0.9 Hz in Haegens et al.). In contrast, IAF between-subject variability is much larger (2.9 Hz in Haegens), which would require a much

larger sample of both responders and non-responders given the effect size observed here.

In conclusion, we propose a new quantitative and automatic measure to track response to therapy in focal epilepsy. Future prospective studies are needed to validate this finding.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Ethics statement

The studies involving humans were approved by Padua University Hospital's ethics committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

CP: Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing. DS: Writing – original draft, Writing – review & editing. GP: Writing – review & editing. FD: Writing – review & editing. BK: Writing – review & editing. LP: Writing – review & editing. GD: Writing – review & editing. AG: Writing – review & editing. MC: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. FF: Conceptualization, Data curation, Supervision, Writing – original draft, Writing – review & editing.

References

- Adeli, H., Ghosh-Dastidar, S., and Dadmehr, N. (2008). A spatio-temporal wavelet-chaos methodology for EEG-based diagnosis of Alzheimer's disease. *Neurosci. Lett.* 444, 190–194. doi: 10.1016/j.neulet.2008.08.008
- Ahmadlou, M., and Adeli, H. (2012). Visibility graph similarity: a new measure of generalized synchronization in coupled dynamic systems. *Physica D* 241, 326–332. doi: 10.1016/j.physd.2011.09.008
- Ahmadlou, M., Adeli, H., and Adeli, A. (2012a). Fractality analysis of frontal brain in major depressive disorder. *Int. J. Psychophysiol.* 85, 206–211. doi: 10.1016/j.ijpsycho.2012.05.001
- Ahmadlou, M., Adeli, H., and Adeli, A. (2012b). Improved visibility graph fractality with application for the diagnosis of autism Spectrum disorder. *Physica A Stat. Mech. Appl.* 391, 4720–4726. doi: 10.1016/j.physa.2012.04.025
- Barbati, G., Porcaro, C., Zappasodi, F., Rossini, P. M., and Tecchio, F. (2004). Optimization of an independent component analysis approach for artifact identification and removal in magnetoencephalographic signals. *Clin. Neurophysiol.* 115, 1220–1232. doi: 10.1016/j.clinph.2003.12.015
- Borri, A., Cerasa, A., Tonin, P., Citrigno, L., and Porcaro, C. (2022). Characterizing fractal genetic variation in the human genome from the Hapmap project. *Int. J. Neural Syst.* 32:2250028. doi: 10.1142/S0129065722500289
- Cattani, C., and Pierro, G. (2013). On the fractal geometry of DNA by the binary image analysis. *Bull. Math. Biol.* 75, 1544–1570. doi: 10.1007/s11538-013-9859-9
- Chatrjian, G. E., Bergamini, L., Dondey, M., Klass, D. W., Lennox-Buchthal, M., and Petersen, I. (1974). A glossary of terms most commonly used by clinical electroencephalographers. *Electroencephalogr. Clin. Neurophysiol.* 37, 538–548. doi: 10.1016/0013-4694(74)90099-6
- Cho, J. R., Koo, D. L., Joo, E. Y., Yoon, S. M., Ju, E., Lee, J., et al. (2012). Effect of levetiracetam monotherapy on background EEG activity and cognition in drug-naïve epilepsy patients. *Clin. Neurophysiol.* 123, 883–891. doi: 10.1016/j.clinph.2011.09.012
- Clemens, B. (2008). Valproate decreases EEG synchronization in a use-dependent manner in idiopathic generalized epilepsy. *Seizure* 17, 224–233. doi: 10.1016/j.seizure.2007.07.005
- Clemens, B., Pirok, P., Bessenyei, M., and Hollódy, K. (2007). Lamotrigine decreases EEG synchronization in a use-dependent manner in patients with idiopathic generalized epilepsy. *Clin. Neurophysiol.* 118, 910–917. doi: 10.1016/j.clinph.2006.11.016
- Clemens, B., Puskás, S., Besenyei, M., Kovács, N. Z., Spisák, T., Kis, S. A., et al. (2014). Valproate treatment normalizes EEG functional connectivity in successfully treated idiopathic generalized epilepsy patients. *Epilepsy Res.* 108, 1896–1903. doi: 10.1016/j.eplepsyres.2014.09.032
- Cole, S. R., van der Meij, R., Peterson, E. J., de Hemptinne, C., Starr, P. A., and Voytek, B. (2017). Nonsinusoidal beta oscillations reflect cortical pathophysiology in Parkinson's disease. *J. Neurosci.* 37, 4830–4840. doi: 10.1523/JNEUROSCI.2208-16.2017
- Cole, S. R., and Voytek, B. (2017). Brain oscillations and the importance of waveform shape. *Trends Cogn. Sci.* 21, Elsevier Ltd, 137–149. doi: 10.1016/j.tics.2016.12.008
- Comanducci, A., Boly, M., Claassen, J., De Lucia, M., Gibson, R. M., Juan, E., et al. (2020). Clinical and advanced neurophysiology in the prognostic and diagnostic evaluation of disorders of consciousness: Review of an IFCN-endorsed expert group. *Clin. Neurophysiol.* Elsevier Ireland Ltd 131, 2736–2765.
- Corcoran, A. W., Alday, P. M., Schlesewsky, M., and Bornkessel-Schlesewsky, I. (2018). Toward a reliable, automated method of individual alpha frequency (IAF) quantification. *Psychophysiology* 55:e13064. doi: 10.1111/psyp.13064
- Cottone, C., Cancelli, A., Pasqualetti, P., Porcaro, C., Salustri, C., and Tecchio, F. (2018). A new, high-efficacy, noninvasive transcranial electric stimulation tuned to local neurodynamics. *J. Neurosci.* 38, 586–594. doi: 10.1523/JNEUROSCI.2521-16.2017

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was partially supported by the Italian Institute of Health, Grant GR-2016-02361802 (to FF). This work was partially supported by PRIN Codice MUR 20228ARNXS (to CP).

Acknowledgments

We thank Marco Zacchello for his work in the early stages of this manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

- Cottone, C., Porcaro, C., Cancelli, A., Olejarczyk, E., Salustri, C., and Tecchio, F. (2017). Neuronal electrical ongoing activity as a signature of cortical areas. *Brain Struct. Funct.* 222, 2115–2126. doi: 10.1007/s00429-016-1328-4
- Di Ieva, A., Esteban, F. J., Grizzi, F., Klonowski, W., and Martin-Landrove, M. (2015). Fractals in the neurosciences, part II: Clinical applications and future perspectives. *Neuroscientist*. SAGE Publications Inc 21, 30–43. doi: 10.1177/1073858413513928
- Di Ieva, A., Grizzi, F., Jelinek, H., Pellionisz, A. J., and Losa, G. A. (2014). Fractals in the neurosciences, part I: General principles and basic neurosciences. *Neuroscientist*. SAGE Publications Inc 20, 403–417. doi: 10.1177/1073858413513927
- Dowsett, J., and Herrmann, C. S. (2016). Transcranial alternating current stimulation with sawtooth waves: simultaneous stimulation and EEG recording. *Front. Hum. Neurosci.* 10:135. doi: 10.3389/fnhum.2016.00135
- Feingold, J., Gibson, D. J., Depasquale, B., and Graybiel, A. M. (2015). Bursts of beta oscillation differentiate postperformance activity in the striatum and motor cortex of monkeys performing movement tasks. *Proc. Natl. Acad. Sci. USA* 112, 13687–13692. doi: 10.1073/pnas.1517629112
- Fink, M. (2010). Remembering the lost neuroscience of pharmaco-EEG. *Acta Psychiatr. Scand.* 121, 161–173. doi: 10.1111/j.1600-0447.2009.01467.x
- Fiorenzato, E., Moaveninejad, S., Weis, L., Biundo, R., Antonini, A., and Porcaro, C. (2024). Brain dynamics complexity as a signature of cognitive decline in Parkinson's disease. *Mov. Disord.* 39, 305–317. doi: 10.1002/mds.29678
- Fröhlich, F. (2015). Experiments and models of cortical oscillations as a target for noninvasive brain stimulation. *Prog. Brain Res.* Elsevier B.V., 41–73. doi: 10.1016/b.pbr.2015.07.025
- Fröhlich, F., and McCormick, D. A. (2010). Endogenous electric fields may guide neocortical network activity. *Neuron* 67, 129–143. doi: 10.1016/j.neuron.2010.06.005
- Galderisi, S., Maj, M., Mucci, A., Bucci, P., and Kemali, D. (1994). QEEG Alpha changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. *Biol. Psychiatry* 35, 367–374. doi: 10.1016/0006-3223(94)90002-7
- Goldberger, A. L. (2001). Heartbeats, hormones, and health - is variability the spice of life. *Am. J. Respir. Crit. Care Med.* 163, 1289–1290. doi: 10.1164/ajrccm.163.6.ed1801a
- Goldberger, A. L., Amaral, L. A. N., Hausdorff, J. M., Ivanov, P. C., Peng, C. K., and Eugene Stanley, H. (2002). Self-organized complexity in the physical, biological, and social sciences. *Sciences [Internet]* 99, 2466–2472. doi: 10.1073/pnas.012579499
- Guo, J., Wang, D., Ren, M., Xiong, B., Li, Z., Wang, X., et al. (2014). QPEEG analysis of the effects of sodium valproate on adult Chinese patients with generalized tonic-clonic seizures. *Metab. Brain Dis.* 29, 801–807. doi: 10.1007/s11011-014-9561-0
- Haegens, S., Cousijn, H., Wallis, G., Harrison, P. J., and Nobre, A. C. (2014). Inter- and intra-individual variability in alpha peak frequency. *NeuroImage* 92, 46–55. doi: 10.1016/j.neuroimage.2014.01.049
- Higuchi, T. (1988). Approach to an irregular time series on the basis of the fractal theory. *Physica D* 31, 277–283. doi: 10.1016/0167-2789(88)90081-4
- Iosifescu, D. V. (2011). Electroencephalography-derived biomarkers of antidepressant response. *Harv. Rev. Psychiatry* 19, 144–154. doi: 10.3109/10673229.2011.586549
- Jobert, M., Wilson, F. J., Ruigt, G. S. F., Brunovsky, M., Pritchep, L. S., and WHIM, D. (2012). Guidelines for the recording and evaluation of pharmaco-EEG data in man: The international pharmaco-EEG society (IPEG): The IPEG pharmaco-EEG guideline committee. *Neuropsychobiology*. S. Karger AG 66, 201–220. doi: 10.1159/000343478
- Jones, S. R. (2016). When brain rhythms aren't 'rhythmic': Implication for their mechanisms and meaning. *Curr. Opin. Neurobiol.* Elsevier Ltd 40, 72–80. doi: 10.1016/j.conb.2016.06.010
- Jouny, C. C., and Bergey, G. K. (2012). Characterization of early partial seizure onset: frequency, complexity and entropy. *Clin. Neurophysiol.* 123, 658–669. doi: 10.1016/j.clinph.2011.08.003
- Khoa, T. Q. D., Ha, V. Q., and Van, T. V. (2012). Higuchi fractal properties of onset epilepsy electroencephalogram. *Comput. Math. Methods Med.* 2012:461426, 1–6. doi: 10.1155/2012/461426
- Klonowski, W. (2009). Everything you wanted to ask about EEG but were afraid to get the right answer. *Nonlin. Biomed. Phys.* 3:2. doi: 10.1186/1753-4631-3-2
- Koutroumanidis, M., Arzimanoglou, A., Caraballo, R., Goyal, S., Kaminska, A., Laoprasert, P., et al. (2017a). The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE neurophysiology task force (part 2). *Epileptic Disord.* 19, 385–437. doi: 10.1684/epd.2017.0952
- Koutroumanidis, M., Arzimanoglou, A., Caraballo, R., Goyal, S., Kaminska, A., Laoprasert, P., et al. (2017b). The role of EEG in the diagnosis and classification of the epilepsy syndromes: a tool for clinical practice by the ILAE neurophysiology task force (part 1). *Epileptic Disord.* 19, 233–298. doi: 10.1684/epd.2017.0935
- Lanzone, J., Ricci, L., Tombini, M., Boscarino, M., Mecarelli, O., Pulitano, P., et al. (2021). The effect of Perampnel on EEG spectral power and connectivity in patients with focal epilepsy. *Clin. Neurophysiol.* 132, 2176–2183. doi: 10.1016/j.clinph.2021.05.026
- Lee, C. Y. (2020). The fractal dimension as a measure for characterizing genetic variation of the human genome. *Comput. Biol. Chem.* 87:107278. doi: 10.1016/j.combiolchem.2020.107278
- Lundqvist, M., Rose, J., Herman, P., Brincat, S. L. L., Buschman, T. J. J., and Miller, E. K. (2016). Gamma and Beta bursts underlie working memory. *Neuron* 90, 152–164. doi: 10.1016/j.neuron.2016.02.028
- Marino, M., Liu, Q., Samogin, J., Tecchio, F., Cottone, C., Mantini, D., et al. (2019). Neuronal dynamics enable the functional differentiation of resting state networks in the human brain. *Hum. Brain Mapp.* 40, 1445–1457. doi: 10.1002/hbm.24458
- Moaveninejad, S., D'Onofrio, V., Tecchio, F., Ferracuti, F., Iarlori, S., Monteriù, A., et al. (2024). Fractal Dimension as a discriminative feature for high accuracy classification in motor imagery EEG-based brain-computer interface. *Comput Methods Programs Biomed.* 244:107944. doi: 10.1016/j.cmpb.2023.107944
- Mucci, A., Volpe, U., Merlotti, E., Bucci, P., and Galderisi, S. (2006). Pharmaco-EEG in psychiatry. *Clin. EEG Neurosci.* 37, 81–98. doi: 10.1177/155005940603700206
- Olejarczyk, E., Cukic, M., Porcaro, C., Zappasodi, F., and Tecchio, F. (2024). Clinical Sensitivity of Fractal Neurodynamics. *Adv Neurobiol.* 36, 285–312. doi: 10.1007/978-3-031-47606-8_15
- Olejarczyk, E. (2003). *Analysis of EEG signals using fractal dimension*. Warsaw: Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences.
- Park, T., Lee, M., Jeong, T., Il, S. Y., and Park, S. M. (2020). Quantitative analysis of eeg power spectrum and emg median power frequency changes after continuous passive motion mirror therapy system. *Sensors (Switzerland)* 20:2354. doi: 10.3390/s20082354
- Pellegrino, G., Mecarelli, O., Pulitano, P., Tombini, M., Ricci, L., Lanzone, J., et al. (2018). Eslicarbazepine acetate modulates EEG activity and connectivity in focal epilepsy. *Front. Neurol.* 9:9. doi: 10.3389/fneur.2018.01054
- Porcaro, C., Cottone, C., Cancelli, A., Rossini, P. M., Zito, G., and Tecchio, F. (2019). Cortical neurodynamics changes mediate the efficacy of a personalized neuromodulation against multiple sclerosis fatigue. *Sci. Rep.* 9:18213. doi: 10.1038/s41598-019-54595-z
- Porcaro, C., Di Lorenzo, G., Seri, S., Pierelli, F., Tecchio, F., and Coppola, G. (2017). Impaired brainstem and thalamic high-frequency oscillatory EEG activity in migraine between attacks. *Cephalalgia* 37, 915–926. doi: 10.1177/0333102416657146
- Porcaro, C., Di Renzo, A., Tinelli, E., Di Lorenzo, G., Parisi, V., Caramia, F., et al. (2020b). Haemodynamic activity characterization of resting state networks by fractal analysis and thalamocortical morphofunctional integrity in chronic migraine. *J. Headache Pain* 21:112. doi: 10.1186/s10194-020-01181-8
- Porcaro, C., Di Renzo, A., Tinelli, E., Di Lorenzo, G., Seri, S., Di Lorenzo, C., et al. (2021). Hypothalamic structural integrity and temporal complexity of cortical information processing at rest in migraine without aura patients between attacks. *Sci. Rep.* 11:18701. doi: 10.1038/s41598-021-98213-3
- Porcaro, C., Marino, M., Carozzo, S., Russo, M., Ursino, M., Ruggiero, V., et al. (2022). Fractal dimension feature as a signature of severity in disorders of consciousness: an EEG study. *Int. J. Neural Syst.* 32:2250031. doi: 10.1142/S0129065722500319
- Porcaro, C., Mayhew, S. D., Marino, M., Mantini, D., and Bagshaw, A. P. (2020a). Characterisation of Haemodynamic activity in resting state networks by fractal analysis. *Int. J. Neural Syst.* 30:2050061. doi: 10.1142/S0129065720500616
- Porcaro, C., Medaglia, M. T., and Krott, A. (2015). Removing speech artifacts from electroencephalographic recordings during overt picture naming. *NeuroImage* 105, 171–180. doi: 10.1016/j.neuroimage.2014.10.049
- Porcaro, C., Moaveninejad, S., D'Onofrio, V., and Di Ieva, A. (2024). Fractal time series: background, estimation methods, and performances. *Adv Neurobiol.* 36, 95–137. doi: 10.1007/978-3-031-47606-8_5
- Ramon, C., and Holmes, M. D. (2015). Spatiotemporal phase clusters and phase synchronization patterns derived from high density EEG and ECoG recordings. *Curr. Opin. Neurobiol.* Elsevier Ltd 31, 127–132. doi: 10.1016/j.conb.2014.10.001
- Ramsay, I. S., Lynn, P., Schermitzler, B., and Sponheim, S. (2021). Individual alpha peak frequency is slower in schizophrenia and related to deficits in visual perception and cognition. *Sci. Rep.* 11:20497. doi: 10.1038/s41598-021-97303-6
- Reynolds, A., Vranic-Peters, M., Lai, A., Grayden, D. B., Cook, M. J., and Peterson, A. (2023). Prognostic interictal electroencephalographic biomarkers and models to assess antiseizure medication efficacy for clinical practice: A scoping review. *Epilepsia*. John Wiley and Sons Inc 64, 1125–1174. doi: 10.1111/epi.17548
- Ricci, L., Assenza, G., Pulitano, P., Simonelli, V., Vollero, L., Lanzone, J., et al. (2021). Measuring the effects of first antiepileptic medication in temporal lobe epilepsy: predictive value of quantitative-EEG analysis. *Clin. Neurophysiol.* 132, 25–35. doi: 10.1016/j.clinph.2020.10.020
- Rodríguez-Bermúdez, G., and García-Laencina, P. J. (2015). Analysis of EEG signals using nonlinear dynamics and chaos: a review. *Appl. Math. Inf. Sci.* 9, 2309–2321. doi: 10.12785/amis/090512
- Scheffer, I. E., Berkovic, S., Capovilla, G., Connolly, M. B., French, J., Guilhoto, L., et al. (2017). ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia* 58, 512–521. doi: 10.1111/epi.13709
- Schomer, D. L., and Lopes Da Silva, F. (2012). *Niedermeyer's electroencephalography: Basic principles, clinical applications, and related fields*, 7 edn (New York: Oxford Academic).

- Smits, F. M., Porcaro, C., Cottone, C., Cancelli, A., Rossini, P. M., and Tecchio, F. (2016). Electroencephalographic fractal dimension in healthy ageing and Alzheimer's disease. *PLoS One* 11:e0149587. doi: 10.1371/journal.pone.0149587
- Somers, D., and Kopell, N. (1993). Rapid synchronization through fast threshold modulation. *Biol. Cybern.* Springer-Verlag 68, 393–407. doi: 10.1007/BF00198772
- Stam, C. J. (2005). Nonlinear dynamical analysis of EEG and MEG: review of an emerging field. *Clin. Neurophysiol.* 116, 2266–2301. doi: 10.1016/j.clinph.2005.06.011
- Viana, P. F., Remvig, L. S., Duun-Henriksen, J., Glasstetter, M., Dümpelmann, M., Nurse, E. S., et al. (2021). Signal quality and power spectrum analysis of remote ultra long-term subcutaneous EEG. *Epilepsia* 62, 1820–1828. doi: 10.1111/epi.16969
- Zappasodi, F., Olejarczyk, E., Marzetti, L., Assenza, G., Pizzella, V., and Tecchio, F. (2014). Fractal dimension of EEG activity senses neuronal impairment in acute stroke. *PLoS One* 9:e100199. doi: 10.1371/journal.pone.0100199
- Zhang, D., and Raichle, M. E. (2010). Disease and the brain's dark energy. *Nat. Rev. Neurol.* 6, 15–28. doi: 10.1038/nrneuro.2009.198